<p>Monte Rosa Therapeutics Inc. announced that Edmund Dunn will retire from his role as Senior Vice President, Corporate Controller and Principal Accounting Officer, effective April 3, 2026. Matthew Bowen, who has held various finance roles at the company since 2021, will succeed Dunn in these positions. Bowen previously worked at Ernst &amp; Young LLP and is a licensed Certified Public Accountant. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-044616), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Reuters

iShares Global Healthcare

Health Care Select Sector SPDR

iShares US Pharma

Monte Rosa Therapeutics

VanEck Biotech ETF

VG Health

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Monte Rosa Therapeutics Appoints Matthew Bowen as Corporate Controller